AbbVie Announces $1.4B Investment in North Carolina

AbbVie is investing $1.4 billion to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, which will integrate advanced manufacturing and laboratory technologies with artificial intelligence (AI) to support the production of AbbVie’s immunology, neuroscience and oncology medicines.

This marks AbbVie’s first major investment in North Carolina. The AbbVie Durham campus, located near Research Triangle Park, was selected for the strength of the region’s local workforce and its ability to support future expansion.

“Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States,” said Robert A. Michael, Chairman and CEO, AbbVie. “By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”

Over the next four years, AbbVie plans to hire 734 people, including engineers, scientists, manufacturing operators and laboratory technicians. The project will also generate more than 2,000 construction jobs during campus development.

This project is part of the Company’s $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade. Most recently, the company announced a $380 billion investment in North Chicago to support the production of AbbVie’s next-gen neuroscience and obesity medications.

Construction will begin this year, with completion expected by the end of 2028.